Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
07 August 2008 - 1:30AM
PR Newswire (US)
The Trial Demonstrated the Safety and Efficacy of the ORMD 0801-
Oral Insulin Capsule JERUSALEM, Israel, August 6
/PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB:
ORMP)(http://www.oramed.com/), a developer of oral delivery
systems, announced today successful results from the clinical trial
of its oral insulin capsule, ORMD 0801. The trial demonstrated that
the product had a good safety profile and was well tolerated and
effective in lowering blood glucose levels in patients with type 2
diabetes. The study was conducted at Hadassah University Medical
Center in Jerusalem and was a continuation of the successful Phase
1B trials that Oramed completed earlier this year. This trial was
the first to expose patients with type 2 diabetes to ORMD 0801 and
its primary goals were to assess the safety, tolerability and
pharmcodynamic effects in these patients. ORMD 0801 was well
tolerated by all patients and had a good safety profile; no serious
adverse events were encountered throughout the study. In 6 of the 9
subjects analyzed, statistically significant reductions in glucose
as well as C-peptide were observed. "We are pleased with the
results from the Phase 2A trial as they showed that ORMD 0801 was
effective and there were no safety issues," said Oramed's Chief
Scientist, Dr. Miriam Kidron. "We look forward to our next phase of
testing and taking the next steps towards making an oral insulin
capsule a reality for millions of diabetics around the world."
About Oramed Pharmaceuticals Oramed Pharmaceuticals is a technology
pioneer in the field of oral delivery solutions for drugs and
vaccines presently delivered via injection. Oramed is seeking to
revolutionize the treatment of diabetes through its patented
flagship product, an orally ingestible insulin capsule currently in
phase 2 clinical trials. Established in 2006, Oramed's technology
is based on over 25 years of research by top research scientists at
Jerusalem's Hadassah Medical Center. The Company's corporate and
R&D headquarters are based in Jerusalem. For more information,
please visit http://www.oramed.com/ Forward-looking statements Some
of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the
progress, timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company's
ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please
refer to the company's filings with the Securities and Exchange
Commission for a comprehensive list of risk factors that could
cause actual results, performance or achievements of the company to
differ materially from those expressed or implied in such forward
looking statements. The company undertakes no obligation to update
or revise any forward-looking statements. Company and Investor
Relation Contacts: Oramed Pharmaceuticals Eric Rosenberg Cell:
+972-54-566-7713 Office: +972-2-566-0001 Email: Media Contacts:
Ruder Finn Israel for Oramed Matthew Krieger Cell: +972-54-467-6950
Office: +972-2-589-2003 Email: DATASOURCE: Oramed Pharmaceuticals
Inc. CONTACT: Company and Investor Relation Contacts: Oramed
Pharmaceuticals, Eric Rosenberg, Cell: +972-54-566-7713, Office:
+972-2-566-0001, Email: ; Media Contacts: Ruder Finn Israel for
Oramed, Matthew Krieger, Cell: +972-54-467-6950, Office:
+972-2-589-2003, Email:
Copyright